Design of [R-(Z)]-(+)-α-(methoxyimino)-1-azabicyclo[2.2.2]octane-3- acetonitrile (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere

Journal of Medicinal Chemistry

Volumn 40, Issue 26, 1997, Pages 4265-4280

  Bromidge, Steven M ^a   Brown, Frank ^a   Cassidy, Frederick ^a   Clark, Michael S G ^a   Dabbs, Steven ^a   Hadley, Michael S ^a   Hawkins, Julie ^a   Loudon, Julia M ^a   Naylor, Christopher B ^a   Orlek, Barry S ^a   Riley, Graham J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ARECOLINE; ATROPINE METHYL NITRATE; CARBACHOL; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; OXOTREMORINE; PARTIAL AGONIST; QUINUCLIDINYL BENZILATE; RECEPTOR SUBTYPE; SABCOMELINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR EFFECT; CHO CELL; CONTROLLED STUDY; DRUG COMPETITION; DRUG DESIGN; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; HIPPOCAMPUS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TREMOR;

ALZHEIMER DISEASE; ANIMALS; BINDING SITES; BLOOD PRESSURE; BRAIN; CHO CELLS; CRICETINAE; ELECTROENCEPHALOGRAPHY; HEART RATE; HUMANS; IMINES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUSCARINIC AGONISTS; PROTEIN BINDING; QUINUCLIDINES; RATS; RATS, INBRED STRAINS; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC; RECOMBINANT PROTEINS; STEREOISOMERISM; TREMOR;

EID: 6844260515     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9702903     Document Type: Article

References (47)

1. Araujo, D. M.; Lapchak, P. A.; Robitaille, Y.; Gauthier, S.; Quirion, R. Differential Alteration of Various Cholinergic Markers in Cortical and Subcortical Regions of Human Brain in Alzheimer's Disease. J. Neurochem. 1988, 50, 1914-1923.
2. Mash, D. C.; Flynn, D. D.; Potter, L. T. Loss of M2 Muscarine Receptors in the Cerebral Cortex in Alzheimer's Disease and Experimental Cholinergic Denervation. Science 1985, 228, 1115-1117.
3. Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science 1982, 217, 408-417.
4. Tariot, P. N; Cohen, R. M.; Welkowitz, J. A; Sunderland, T; Newhouse, P. A; Murphy, D. L.; Weingartner, H. Multiple-dose Arecoline Infusions in Alzheimer's Disease. Arch. Gen. Psychiatry 1988, 45, 901-905.
5. Hollander, E.; Davidson, M.; Mohs, R. C.; Horvath, T. B.; Davis, B. M.; Zemishlany, Z.; Davis, K. L. RS 86 in the Treatment of Alzheimer's Disease: Cognitive and Biological Effects. Biol. Psychiatry 1987, 22, 1067-1078.
6. Cassidy, P.; Orlek, B. S.; Hadley, M. S. Chemical Approaches to the Enhancement of Cholinergic Function for the Treatment of Senile Dementia. In Anti-Dementia Agents; Nicholson, D., Ed., Academic Press: London, 1994; pp 33-83.
7. Bonner, T. I. The Molecular Basis of Muscarinic Receptor Diversity, Trends Neurosci. 1989, 72, 148-151.
8. Levey, A. I. Immunological Localization Of m1-m5 Muscarinic Acetylcholine Receptors In Peripheral Tissues and Brain. Life Sci. 1993, 52, 441-448.
9. Buckley, N. J.; Bonner, T. I.; Buckley, C. M.; Brann, M. R. Antagonist Binding Properties of Five Cloned Muscarinic Receptors Expressed in CHO-K1 Cells. Mol. Pharmacol. 1989, 35, 469-476.
10. Tecle, H.; Lauffer, D. J.; Mirzadegan, T.; Moos, W. H.; Moreland, D. W.; Pavia, M. R.; Schwarz, R. D.; Davis, R. E. A Rationale for the Design and Synthesis of ml Selective Muscarinic Agonists. Bioorg. Med. Chem. Lett. 1992, 2, 821-826.
11. Kenakin, T. P. Tissue and Receptor Selectivity: Similarities and Differences. Adv. Drug Res. 1986, 16, 71-109.
12. Orlek, B. S.; Blaney, F. E.; Brown, F.; Clark, M. S. G.; Hadley, M. S.; Hatcher, J.; Riley, G. J.; Rosenberg, H. E.; Wadsworth, H. J.; Wyman, P. Comparison of Azabicyclic Esters and Oxadiazoles as Ligands for the Muscarinic Receptor, J. Med. Chem. 1991, 34, 2726-2735.
13. Wadsworth, H. J.; Jenkins, S. M.; Orlek, B. S.; Cassidy, F.; Clark, M. S. G.; Brown, F.; Riley, G. J.; Graves, D.; Hawkins, J.; Naylor, C. Synthesis and Muscarinic Activities of Quinuclidin-3-yl Triazole and Tetrazole Derivatives. J. Med. Chem. 1992, 35, 1280-1290.
14. Jenkins, S. M.; Wadsworth, H. J.; Bromidge, S.; Orlek, B. S.; Wyman, P. A.; Riley, G. J.; Hawkins, J. Substituent Variation in Azabicyclic Triazole- and Tetrazole-Based Muscarinic Receptor Ligands. J. Med. Chem. 1992, 35, 2392-2406.
15. Orlek, B. S.; Cassidy, F.; Clark, M. S. G.; Faulkner, R. E.; Collings, E. J.; Hawkins, J.; Riley, G. J. Design and Synthesis of Novel Muscarinic Agonists Containing the 1,2,4-triazine ring as an Ester Bioieostere. Bioorg. Med. Chem. Lett. 1994, 4, 1411-1414.
16. Toja, E.; Bonetti, C.; Butti, A.; Hunt, P.; Fortin, M.; Barzaghi, F.; Formento, M. L.; Maggioni, A.; Nencioni, A.; Galliani, G. 1-Alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl Oximes: A New Class of Potent Orally Active Muscarinic Agonists Related to Arecoline. Eur. J. Med. Chem. 1991, 26, 853-868.
17. For preliminary accounts of this work, see: Bromidge, S. M.; Brown, F.; Cassidy, F.; Clark, M. S. G.; Dabbs, S. Hadley, M. S.; Loudon, J. M.; Orlek, B. S.; Riley, G. J. Design and Synthesis of Azabicyclic Muscarinic Agonists Incorporating an Oxime Ether Functionality. Bioorg. Med. Chem. Lett. 1992, 2, 787-790.
18. Bromidge, S. M.; Brown, F.; Cassidy, F.; Clark, M. S. G.; Dabbs, S.; Hawkins, J.; Loudon, J. M.; Orlek, B. S.; Riley, G. J. A Novel and Selective Class of Azabicyclic Muscarinic Agonists Incorporating an N-Methoxy Imidoyl Halide or Nitrile Functionality. Bioorg. Med. Chem. Lett. 1992, 2, 791-796.
19. Nahm, S.; Weinreb, S. M. N-Methoxy-N-methylamides as Effective Acylating Agents. Tetrahedron Lett. 1981, 22, 3815-3818.
20. Appel, R. Tertiary Phosphane/Tetrachloromethane, a Versatile Reagent for Chlorination, Dehydration, and P-N Linkage. Angew. Chem., Int. Ed. Engl. 1975, 14 (12), 801-811.
21. Clarke, J. H.; Hyde, A. J., Smith, D. K. Calcium Fluoride-supported Alkali Metal Fluorides. New Reagents for Nucleophilic Fluorine Transfer Reactions. J. Chem. Soc., Chem. Commun. 1986, 791-793.
22. Poziomek, E. J.; Melvin, A. R. A New Synthetic Route to a-Isonitrosoacetonitriles. The Chlorination of Isonicotinaldehyde Oxime. J. Org. Chem. 1961, 26, 3769-3771.
23. Jacques, J.; Fouquey, C. Enantiomeric Cyclic Binaphthyl Phosphoric Acids as Resolving Agents. Tetrahedron Lett. 1971, 48, 4617-4620.
24. Bromidge, S. M.; Cassidy, F.; Clark, M. S. G.; Eggleston, D. S.; Orlek, B. S. Synthesis and Properties of [R-(Z)-(+)-a-(1-Azabicyclo-[2.2.2]oct-3-yl)-a-(methoxyimino)acetonitrile, a Novel Selective Muscarinic Agonist. J. Chem. Soc., Chem. Commun. 1994, 2189-2190.
25. McCarty, C. G. syn-anti Isomerizations and rearrangements. In The Chemistry of the Carbon-Nitrogen Double Bond; Patai, S., Ed.; Wiley: New York, 1970; pp 383-392 and references cited therein.
26. Lambrecht, G.; Mutschler, E. Cyclic Analogues of Agonists as a Tool for Structure-Activity Relationships. In Medicinal Chemistry Advances, Proceedings of the Seventh International Symposium on Medicinal Chemistry, Torremolinos, Spain 2-5 September 1980; De Las Heras, F. G., Vega, S., Eds.; Pergammon Press: Oxford, 1981; pp 117-129.
27. Silipo, C.; Vittoria, A. Three-dimensional Structure of Drugs. In Comprehensive Medicinal Chemistry; Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: 1990; Vol. 4, pp 196-198.
28. Schwarz, R. D.; Davis, R. E.; Jaen, J. C.; Spencer, C. J.; Tecle, H.; Thomas, A. J. Characterisation of Muscarinic Agonists in Recombinant Cell Lines. Life Sci. 1993, 52, 465-472.
29. Hawkins, J.; Riley, G. J.; Brown, F.; Clark, M. S. G. Neurode-generation of Alzheimer Type: Muscarinic Agonists for Counteracting the Deficit. Selectivity Studies on Human Muscarinic Receptor Sub-types hm1-hm4 Expressed in CHO Cells. In Neurodegeneration; Hunter, A. J., Clark, M., Eds.; Academic Press: London, 1992; pp 240-241.
30. Bevan, P. Effect of Muscarinic Ligands on the Electrical Activity Recorded from the Hippocampus: A Quantitative Approach. Br. J. Pharmacol. 1984, 82, 431-440.
31. Loudon, J.; Brown, F.; Clark, M.; Riley, G. Hippocampal and Cardiovascular Effects of Muscarinic Agents. Key Topics In Brain Research. 1990, Alzheimer's Disease. Epidemiology, Neuropathology, Neurochemistry, and Clinics, 229-233.
32. Barnes, J. C.; Roberte, F. F. Central Effects of Muscarinic Agonists and Antagonists on Hippocampal Theta Rhythm and Blood pressure in the Anaesthetised Rat. Eur. J. Pharmacol. 1991, 195, 233-240.
33. Eglen, R. M.; Whiting, R. L. Heterogeneity of Vascular Muscarinic Receptors. J. Auton. Pharmacol. 1990, 19, 233-245.
34. Clague, R. U.; Eglen, R. M.; Strachan, A. C.; Whiting, R. L. Action of Agonists and Antagonists at Muscarinic Receptors Present on Ileum and Atria In Vitro. Er. J. Pharmacol. 1985, 86, 163-170.
35. Ringdahl, B. Selectivity of Partial Agonists Related to Oxotremorine Based On Differences in Muscarinic Receptor Reserve Between the Guinea Pig Ileum and Urinary Bladder. Mol. Pharmacol. 1987, 31, 351-356.
36. Eglen, R. M.; Kenny, B. A.; Michel, A. D.; Whiting, R. L. Muscarinic Activity of McN-A-343 and its Value in Muscarinic Receptor Classification. Br. J. Pharmacol. 1987, 90, 693-700.
37. 1 Muscarinic Receptors. J. Pharmcol. Exp. Ther. 1990, 253, 310-314.
38. Furchgott, R. F.; Cherry, P. D. The Muscarinic Receptor of the Vascular Endothelium that Subserves Vasodilation. Trends Pharmacol. Sci. 1984, 5, 44-48.
39. Freedman, S. B.; Dawson, G. R.; Iversen, L. L.; Baker, R.; Hargreaves, R. J. The Design of Novel Muscarinic Partial Agonists that have Functional Selectivity in Pharmacological Preparations in vitro and Reduced Side Effect Profile in vivo. Life Sci. 1993, 52, 489-495.
40. Grob, C. A.; Kaiser, A.; Renk, E. Electrostatic Effects in the Ground and Excited States of Mesomeric Molecules. Chem. Ind. 1957, 598-599.
41. Scherrer, R. A.; Howard, S. M. Use of Distribution Coefficients in Quantitative Structure-Activity Relationships. J. Med. Chem. 1977, 20, 53-58.
42. Ringdahl, B.; Roch, M.; Jenden, D. J. Regional Differences in Receptor Reserve for Analogs of Oxotremorine in vivo: Implications for Development of Selective Muscarinic Agonists. J. Pharmacol. Exp. Ther. 1987, 242 (2), 464-471.
43. Loudon, J. M.; Hatcher, J. P.; Storey, V. J.; Clark, M. S. G. SB 202026, A Functionally Selective Partial Agonist, Enhances Cognition at Doses which do not induce Side Effects. Neurobiol. Aging 1996, 17 (Suppl.), S30.
44. Grochowski, E.; Jurczak, J. A New Synthesis of O-Alkylhydroxylamines. Synthesis 1976, 682-684.
45. Paxinos, G.; Watson, C. The rat brain in stereotoxic coordinates; Academic Press: Australia, 1982.
46. Tripos Inc., 1699 South Hanley Rd, Suite 303, St. Louis, MO 63144-2913.
47. Gaussian 94, Revision B.3, Frisch, M. J.; Trucks; G. W.; Schlegel H. B.; Gill, P. M. W.; Johnson, B. G.; Robb, M. A.; Cheeseman, J. R.; Keith, T.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Binkley, J. S.; Defrees, D. J.; Baker, J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C.; Pople, J. A. Gaussian, Inc., Pittsburgh, PA, 1995.